At the request of the Centers for Medicare and Medicaid Services (CMS), the Federal Agency for Healthcare Research and Quality (AHRQ) sponsored a technical brief evaluating 245 published studies of skin substitutes from 76 manufacturers. · 22 of the 245 studies met the criteria to be a Randomized Controlled Trial (RCT) · 12 of these 22 RCTs met the inclusion criteria for “low risk-of-bias” · 9 of these 12 studies met primary endpoints 56% of the low risk-of-bias studies that met primary endpoints were on MIMEDX’s products. MIMEDX study quality was validated as best in class. Learn more: https://bit.ly/41W4WdM #MIMEDX #RCT #Research #SkinSubstitutes
